Market Herald logo

Subscribe

Be the first with the news that moves the market
  • iCo Therapeutics (ICO) has completed the Phase 1b dosing for the company’s oral Amphotericin B study. 
  • Results from Phase 1b should be available before the end of 2020’s first quarter.
  • Phase 1b results will be used to improve Phase 2 of the clinical study on vulvovaginal candidiasis (VVC). 
  • iCo’s share price is down 7.14 per cent, with shares trading at $0.06 apiece.

Biotechnology company iCo Therapeutics (ICO), and its Australian subsidiary, have completed Phase 1b dosing for the oral Amphotericin B study.

The ongoing study will test how well the oral form of antifungal drug Amphotericin B can treat vulvovaginal candidiasis (VVC), a yeast infection.  

All subjects in Phase 1b of the study have received varying doses of oral Amphotericin B over 10 days. Subsequent to dosing, subjects have been followed up for an additional 10 days.

The results of the Phase 1b dosing should be available before the end of 2020’s first quarter. iCo’s Chief Medical Officer, Dr Peter Hnik, spoke about how the results will benefit the overall study.

“Results from the Phase 1b study using multiple ascending doses of oral Amphotericin B will provide additional safety and pharmacokinetic information needed for the upcoming Phase 2 clinical study in patients with vulvovaginal candidiasis.”

The Phase 2 study will compare oral Amphotericin B to Fluconazole, another antifungal medication, in a head-to-head study. The Phase 2 study is scheduled to start in 2020’s second quarter.

According to Denning et al, “Worldwide, recurrent vulvovaginal candidiasis affects about 138 million [people] annually, with a global annual prevalence of 3,871 per 100 000 [people]. 372 million [people] are affected by recurrent vulvovaginal candidiasis over their lifetime.”

“By 2030, the population of [people] with recurrent vulvovaginal candidiasis each year is estimated to increase to almost 158 million, resulting in 20,240,664 extra cases […]. In high-income countries, the economic burden from lost productivity could be up to $14.39 billion USD.

iCo’s share price is down 7.14 per cent, with shares trading at $0.06 apiece.

More From The Market Herald

" Theralase (TSXV:TLT) granted Brazilian patent

Theralase (TLT) has expanded its intellectual property portfolio regarding photo dynamic compounds.

" ScreenPro Security (CSE:SCRN) subsidiary Concierge Medical launches Prestige Care

ScreenPro’s (SCRN) operating subsidiary Concierge Medical Consultants has launched Prestige Medical Care (PMC) to private clientele in Vancouver.
Reliq Health Technologies - CEO Dr. Lisa Crossley

" Reliq Health Technologies (TSXV:RHT) announces six new U.S. contracts

Reliq Health Technologies (RHT) has signed contracts with physician practices, home health agencies and nursing facilities in California, Texas, Florida and Puerto Rico.
Datametrex - CEO, Marshall Gunter.

" Datametrex’s (TSXV:DM) Medi-Call app hits Vancouver market

Datametrex’s (DM) Medi-Call app is now available for Android users in Vancouver.